Explore

Trendline Trendline
Humacyte Reports Positive Long-Term Dialysis Data, Boosting Market Position

Humacyte Reports Positive Long-Term Dialysis Data, Boosting Market Position

Humacyte Reports Positive Long-Term Dialysis Data, Boosting Market Position
Rapid Read Rapid Read
Wolters Kluwer Health Survey Reveals Rising AI Use and Concerns Among Clinicians and Patients

Wolters Kluwer Health Survey Reveals Rising AI Use and Concerns Among Clinicians and Patients

A recent survey conducted by Wolters Kluwer Health highlights the increasing use of artificial intelligence (AI) among clinicians and patients. The 2026 Future Ready Healthcare Survey Report, which gathered insights from 355 clinicians and 254 patients nationwide, reveals that 35% of clinicians use AI multiple times daily for work, while 40% of patients use AI at least once daily in their personal lives. The report notes a significant increase in AI usage among physicians and nurses, with physicians' usage tripling from 10% in 2025 to 38% in 2026, and nurses' usage doubling from 16% to 32% year-over-year. Despite the growing adoption, the survey also highlights concerns among both groups regarding AI's implementation in healthcare. Clinicians express worries about 'deskilling' due to overreliance on AI tools, and AI hallucinations, while patients are concerned about accountability if AI contributes to harm during care.
Rapid Read Rapid Read
MannKind Corporation Secures FDA Approval for Afrezza Inhaled Insulin for Children with Diabetes

MannKind Corporation Secures FDA Approval for Afrezza Inhaled Insulin for Children with Diabetes

MannKind Corporation has announced that the U.S. Food and Drug Administration (FDA) has approved Afrezza, an inhaled insulin, for use in children and adolescents aged 6 and older with type 1 and type 2 diabetes. This approval marks a significant advancement in pediatric diabetes care, offering a new mealtime insulin option that is needle-free. Afrezza is administered at the beginning of meals using a small, portable inhaler, allowing for rapid absorption through the lungs. This method closely mimics the body's natural insulin response to meals. The approval is supported by the results of the Phase 3 INHALE-1 study and additional clinical data collected over two decades. Afrezza is now available for eligible patients at a cost of $35 or less per month, with support provided through MannKind Cares.
Rapid Read Rapid Read
Massive Bio Collaborates with TOUCH and Navigating Trials to Enhance Cancer Patients' Access to Clinical Trials

Massive Bio Collaborates with TOUCH and Navigating Trials to Enhance Cancer Patients' Access to Clinical Trials

Massive Bio, a global precision oncology company, has announced a partnership with TOUCH, The Black Breast Cancer Alliance, and Navigating Trials to improve access to clinical trials for cancer patients. This collaboration will integrate Massive Bio's AI-powered trial matching system into the digital platforms of both organizations, providing a seamless and cost-free pathway for patients to find personalized clinical trial options. TOUCH BBCA focuses on supporting breast cancer patients through education and advocacy, while Navigating Trials extends clinical research opportunities to patients across various cancer types. The partnership aims to bridge the gap between patient communities and the clinical research ecosystem, ensuring equitable access to clinical trials.
AP News AP News
Patients find help with therapy donkeys at psychiatric hospital near Paris

Patients find help with therapy donkeys at psychiatric hospital near Paris

Therapy donkeys are helping patients with mental health conditions at a psychiatric hospital near Paris
Trendline Trendline
GE HealthCare Advances Nuclear Medicine with AI and Radiopharmaceutical Innovations

GE HealthCare Advances Nuclear Medicine with AI and Radiopharmaceutical Innovations

GE HealthCare Advances Nuclear Medicine with AI and Radiopharmaceutical Innovations
Trendline Trendline
Paradigm Health Launches New Clinical Trial Solution for Observational Study

Paradigm Health Launches New Clinical Trial Solution for Observational Study

Paradigm Health Launches New Clinical Trial Solution for Observational Study
Trendline Trendline
Veritas Aortic Solutions Secures $12M to Develop Non-Surgical Aortic Treatment

Veritas Aortic Solutions Secures $12M to Develop Non-Surgical Aortic Treatment

Veritas Aortic Solutions Secures $12M to Develop Non-Surgical Aortic Treatment
Rapid Read Rapid Read
Grail's Multi-Cancer Blood Test Shows Mixed Results in Early Detection Trials

Grail's Multi-Cancer Blood Test Shows Mixed Results in Early Detection Trials

Grail, a Silicon Valley healthcare company, has presented its largest study to date on the Galleri blood test at the American Society of Clinical Oncology meeting in Chicago. The test, priced at $950, aims to detect over 50 types of cancer by identifying cancer DNA in the bloodstream. The study involved more than 140,000 older individuals in the UK, assessing the test's ability to detect cancer before it reaches advanced stages. While the test increased cancer detection rates when combined with standard screenings, it was less effective at identifying early-stage cancers, which are generally easier to treat. The test is not yet FDA-approved but is available in the U.S. with a prescription.
Rapid Read Rapid Read
Grail's $950 Cancer Blood Test Shows Mixed Results in Early Detection

Grail's $950 Cancer Blood Test Shows Mixed Results in Early Detection

Grail, a healthcare company, presented its largest study on the Galleri blood test at the American Society of Clinical Oncology meeting. The test, priced at $950, aims to detect over 50 types of cancer early. The study involved over 140,000 participants and showed that while the test increased cancer detection, it missed many early-stage cancers. The test is not FDA-approved but is available with a prescription. Despite its limitations, the test is seen as promising for detecting certain cancers earlier than traditional methods.
Trendline Trendline
Humacyte's Acellular Tissue Engineered Vessel Shows Promising Self-Repair in Dialysis Use

Humacyte's Acellular Tissue Engineered Vessel Shows Promising Self-Repair in Dialysis Use

Humacyte's Acellular Tissue Engineered Vessel Shows Promising Self-Repair in Dialysis Use